Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis
Catherine Frenette,Zeid Kayali,Edward Mena,Parvez S Mantry,Kathryn J Lucas,Guy Neff,Miguel Rodriguez,Paul J Thuluvath,Ethan Weinberg,Bal R Bhandari,James Robinson,Nicole Wedick,Jean L Chan,David T Hagerty,Kris V Kowdley,IDN-6556-17 Study Investigators,Kathleen Corey,David Bernstein,Mazen Noureddin,Nyingi Kemmer,Andrew DeLemos,Nikolaos Pyrsopoulos,William Lee,Marwan Ghabril,Andrew Scanga,Mark McKenzie,Eric Lawitz,Viviana Figueroa-Diaz,Douglas Simonetto,Richard Frederick,Kimberly Brown,George Therapondos,Aasim Sheikh,Danielle Brandman,Lance Stein,Victor Ankoma-Sey,Kalyan Bhamidimarri,Charles Landis,Brett Fortune,Hugo Vargas,Manal Abdelmalek,Bradley Freilich,Don Rockey,John Vierling,Harvey Tatum,Michael Curry,Mitchell Shiffman,Kiran Bambha,Reem Ghalib,Amy Stratton,Nadeem Anwar,Stephen Caldwell,Ayman Koteish,Mohammad Siddiqui,Sammy Saab,Nikunj Shah,Anita Kohli,Mary Rinella,Souvik Sarkar,Dawn Torres,Elizabeth Verna,Ravi Ravendhran,Justin Reynolds,Ray Thomason,Ray Kim,Fernando Membreno,Sofia Jakab,Stevan Gonzalez,Andrew Keaveny,Jen-Jung Pan,Satinder Gill,Jonathan Huang,James Strobel,Amanda Wieland,Giuseppe Morelli,Thomas Amankonah,Marina Roytman,Warren Schmidt,Gary Abrams,Bhaktasharan Patel
DOI: https://doi.org/10.1016/j.jhep.2020.09.029
Abstract:Background & aims: Non-alcoholic steatohepatitis is a leading cause of end-stage liver disease. Hepatic steatosis and lipotoxicity cause chronic necroinflammation and direct hepatocellular injury resulting in cirrhosis, end-stage liver disease and hepatocellular carcinoma. Emricasan is a pan-caspase inhibitor that inhibits excessive apoptosis and inflammation; it has also been shown to decrease portal pressure and improve synthetic function in mice with carbon tetrachloride-induced cirrhosis. Methods: This double-blind, placebo-controlled study randomized 217 individuals with decompensated NASH cirrhosis 1:1:1 to emricasan (5 mg or 25 mg) or placebo. Patients were stratified by decompensation status and baseline model for end-stage liver disease-sodium (MELD-Na) score. The primary endpoint comprised all-cause mortality, a new decompensation event (new or recurrent variceal hemorrhage, new ascites requiring diuretics, new unprecipitated hepatic encephalopathy ≥grade 2, hepatorenal syndrome, spontaneous bacterial peritonitis), or an increase in MELD-Na score ≥4 points. Results: There was no difference in event rates between either of the emricasan treatment groups and placebo, with hazard ratios of 1.02 (95% CI 0.59-1.77; p = 0.94) and 1.28 (95% CI 0.75-2.21; p = 0.37) for 5 mg and 25 mg of emricasan, respectively. MELD-Na score progression was the most common outcome. There was no significant effect of emricasan treatment on MELD-Na score, international normalized ratio, total serum bilirubin, albumin level or Child-Pugh score. Emricasan was generally safe and well-tolerated. Conclusions: Emricasan was safe but ineffective for the treatment of decompensated NASH cirrhosis. However, this study may guide the design and conduct of future clinical trials in decompensated NASH cirrhosis. Lay summary: Patients with decompensated cirrhosis related to non-alcoholic steatohepatitis are at high risk of additional decompensation events and death. Post hoc analyses in previous pilot studies suggested that emricasan might improve portal hypertension and liver function. In this larger randomized study, emricasan did not decrease the number of decompensation events or improve liver function in patients with a history of decompensated cirrhosis related to non-alcoholic steatohepatitis. CLINICALTRIALS. Gov identifier: NCT03205345.